RU2490258C2 - ПРОИЗВОДНЫЕ ГИДРОБЕНЗАМИДА В КАЧЕСТВЕ ИНГИБИТОРОВ Hsp90 - Google Patents
ПРОИЗВОДНЫЕ ГИДРОБЕНЗАМИДА В КАЧЕСТВЕ ИНГИБИТОРОВ Hsp90 Download PDFInfo
- Publication number
- RU2490258C2 RU2490258C2 RU2009117589/04A RU2009117589A RU2490258C2 RU 2490258 C2 RU2490258 C2 RU 2490258C2 RU 2009117589/04 A RU2009117589/04 A RU 2009117589/04A RU 2009117589 A RU2009117589 A RU 2009117589A RU 2490258 C2 RU2490258 C2 RU 2490258C2
- Authority
- RU
- Russia
- Prior art keywords
- formula
- compound
- alkyl
- anticancer drug
- acid addition
- Prior art date
Links
- 239000003481 heat shock protein 90 inhibitor Substances 0.000 title abstract 2
- VUYRFIIFTJICNA-LKNRODPVSA-N (e)-n-[[(e)-benzylideneamino]-phenylmethyl]-1-phenylmethanimine Chemical class C=1C=CC=CC=1/C=N/C(C=1C=CC=CC=1)\N=C\C1=CC=CC=C1 VUYRFIIFTJICNA-LKNRODPVSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract 30
- 238000000034 method Methods 0.000 claims abstract 18
- 150000003839 salts Chemical class 0.000 claims abstract 13
- 239000002253 acid Substances 0.000 claims abstract 10
- JVTAAEKCZFNVCJ-REOHCLBHSA-N L-lactic acid Chemical compound C[C@H](O)C(O)=O JVTAAEKCZFNVCJ-REOHCLBHSA-N 0.000 claims abstract 6
- 230000000694 effects Effects 0.000 claims abstract 3
- 239000000126 substance Substances 0.000 claims abstract 2
- 125000000217 alkyl group Chemical group 0.000 claims 14
- 239000002246 antineoplastic agent Substances 0.000 claims 10
- 229940041181 antineoplastic drug Drugs 0.000 claims 10
- 125000006239 protecting group Chemical group 0.000 claims 7
- 239000012458 free base Substances 0.000 claims 6
- 125000003342 alkenyl group Chemical group 0.000 claims 5
- 238000005984 hydrogenation reaction Methods 0.000 claims 5
- 206010059866 Drug resistance Diseases 0.000 claims 4
- 102100034051 Heat shock protein HSP 90-alpha Human genes 0.000 claims 4
- 101001016865 Homo sapiens Heat shock protein HSP 90-alpha Proteins 0.000 claims 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 3
- 238000009903 catalytic hydrogenation reaction Methods 0.000 claims 3
- 238000006243 chemical reaction Methods 0.000 claims 3
- 230000003993 interaction Effects 0.000 claims 3
- 238000000634 powder X-ray diffraction Methods 0.000 claims 3
- 241000124008 Mammalia Species 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 230000002159 abnormal effect Effects 0.000 claims 2
- 238000010640 amide synthesis reaction Methods 0.000 claims 2
- 210000000481 breast Anatomy 0.000 claims 2
- 201000011510 cancer Diseases 0.000 claims 2
- 239000003054 catalyst Substances 0.000 claims 2
- 230000010261 cell growth Effects 0.000 claims 2
- 210000001072 colon Anatomy 0.000 claims 2
- 230000003247 decreasing effect Effects 0.000 claims 2
- 210000002249 digestive system Anatomy 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 230000002708 enhancing effect Effects 0.000 claims 2
- 210000002615 epidermis Anatomy 0.000 claims 2
- 210000003238 esophagus Anatomy 0.000 claims 2
- 210000000232 gallbladder Anatomy 0.000 claims 2
- 239000003112 inhibitor Substances 0.000 claims 2
- 230000002401 inhibitory effect Effects 0.000 claims 2
- 210000003734 kidney Anatomy 0.000 claims 2
- 210000004185 liver Anatomy 0.000 claims 2
- 210000004072 lung Anatomy 0.000 claims 2
- 230000003211 malignant effect Effects 0.000 claims 2
- 210000003739 neck Anatomy 0.000 claims 2
- 210000001672 ovary Anatomy 0.000 claims 2
- 210000000496 pancreas Anatomy 0.000 claims 2
- 230000002062 proliferating effect Effects 0.000 claims 2
- 210000002307 prostate Anatomy 0.000 claims 2
- 230000035945 sensitivity Effects 0.000 claims 2
- 210000003491 skin Anatomy 0.000 claims 2
- 210000002784 stomach Anatomy 0.000 claims 2
- 210000001685 thyroid gland Anatomy 0.000 claims 2
- 229910052723 transition metal Inorganic materials 0.000 claims 2
- 150000003624 transition metals Chemical class 0.000 claims 2
- 208000010570 urinary bladder carcinoma Diseases 0.000 claims 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims 1
- 229940126601 medicinal product Drugs 0.000 claims 1
- 0 CN(*)c(c(O*)c1)cc(C(C[C@](CC2)Cc3c2ccc(C*2CCC(CC*)CC2)c3)=O)c1O* Chemical compound CN(*)c(c(O*)c1)cc(C(C[C@](CC2)Cc3c2ccc(C*2CCC(CC*)CC2)c3)=O)c1O* 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C67/00—Preparation of carboxylic acid esters
- C07C67/30—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
- C07C67/317—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by splitting-off hydrogen or functional groups; by hydrogenolysis of functional groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
- C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
- C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
- C07C235/60—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/01—Saturated compounds having only one carboxyl group and containing hydroxy or O-metal groups
- C07C59/08—Lactic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
- C07C65/03—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring
- C07C65/05—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups monocyclic and having all hydroxy or O-metal groups bound to the ring o-Hydroxy carboxylic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C67/00—Preparation of carboxylic acid esters
- C07C67/30—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group
- C07C67/313—Preparation of carboxylic acid esters by modifying the acid moiety of the ester, such modification not being an introduction of an ester group by introduction of doubly bound oxygen containing functional groups, e.g. carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
- C07C69/84—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring
- C07C69/92—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of monocyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of a six-membered aromatic ring with etherified hydroxyl groups
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Virology (AREA)
- Dermatology (AREA)
- Transplantation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US82924306P | 2006-10-12 | 2006-10-12 | |
| GB0620259.2 | 2006-10-12 | ||
| US60/829,243 | 2006-10-12 | ||
| GBGB0620259.2A GB0620259D0 (en) | 2006-10-12 | 2006-10-12 | Pharmaceutical compounds |
| PCT/GB2007/003871 WO2008044034A1 (en) | 2006-10-12 | 2007-10-12 | Hydrobenzamide derivatives as inhibitors of hsp90 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2009117589A RU2009117589A (ru) | 2010-11-20 |
| RU2490258C2 true RU2490258C2 (ru) | 2013-08-20 |
Family
ID=37491396
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2009117589/04A RU2490258C2 (ru) | 2006-10-12 | 2007-10-12 | ПРОИЗВОДНЫЕ ГИДРОБЕНЗАМИДА В КАЧЕСТВЕ ИНГИБИТОРОВ Hsp90 |
Country Status (28)
| Country | Link |
|---|---|
| US (2) | US8653084B2 (enExample) |
| EP (2) | EP2081895B1 (enExample) |
| JP (1) | JP5726416B2 (enExample) |
| KR (1) | KR101571568B1 (enExample) |
| CN (1) | CN101848892B (enExample) |
| AU (1) | AU2007306104B2 (enExample) |
| BR (1) | BRPI0719879A8 (enExample) |
| CA (1) | CA2665931C (enExample) |
| CY (2) | CY1113873T1 (enExample) |
| DK (2) | DK2546233T3 (enExample) |
| ES (2) | ES2402903T3 (enExample) |
| GB (1) | GB0620259D0 (enExample) |
| HR (2) | HRP20130255T1 (enExample) |
| HU (1) | HUE037268T2 (enExample) |
| IL (1) | IL197934A (enExample) |
| LT (1) | LT2546233T (enExample) |
| ME (1) | ME01874B (enExample) |
| MX (1) | MX2009003739A (enExample) |
| NO (1) | NO342242B1 (enExample) |
| NZ (1) | NZ576110A (enExample) |
| PL (2) | PL2081895T3 (enExample) |
| PT (2) | PT2081895E (enExample) |
| RS (2) | RS52716B (enExample) |
| RU (1) | RU2490258C2 (enExample) |
| SI (2) | SI2546233T1 (enExample) |
| TW (1) | TWI429638B (enExample) |
| WO (1) | WO2008044034A1 (enExample) |
| ZA (1) | ZA200902270B (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL1877379T3 (pl) | 2005-04-13 | 2013-06-28 | Astex Therapeutics Ltd | Pochodne hydroksybenzamidu i ich wykorzystanie, jako inhibitorów hsp90 |
| US7754725B2 (en) | 2006-03-01 | 2010-07-13 | Astex Therapeutics Ltd. | Dihydroxyphenyl isoindolymethanones |
| US8883790B2 (en) | 2006-10-12 | 2014-11-11 | Astex Therapeutics Limited | Pharmaceutical combinations |
| WO2008044054A2 (en) | 2006-10-12 | 2008-04-17 | Astex Therapeutics Limited | Hydroxy-substituted benzoic acid amide compounds for use in therapy |
| GB0620259D0 (en) | 2006-10-12 | 2006-11-22 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| JP5410285B2 (ja) * | 2006-10-12 | 2014-02-05 | アステックス、セラピューティックス、リミテッド | 医薬化合物 |
| EP2073803B1 (en) | 2006-10-12 | 2018-09-19 | Astex Therapeutics Limited | Pharmaceutical combinations |
| GB0806527D0 (en) | 2008-04-11 | 2008-05-14 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| EP2445340B1 (en) | 2009-06-22 | 2016-05-18 | Millennium Pharmaceuticals, Inc. | Substituted hydroxamic acids and uses thereof |
| AR077405A1 (es) | 2009-07-10 | 2011-08-24 | Sanofi Aventis | Derivados del indol inhibidores de hsp90, composiciones que los contienen y utilizacion de los mismos para el tratamiento del cancer |
| FR2949467B1 (fr) | 2009-09-03 | 2011-11-25 | Sanofi Aventis | Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation |
| GB201009853D0 (en) | 2010-06-11 | 2010-07-21 | Chroma Therapeutics Ltd | HSP90 inhibitors |
| CA2866814C (en) * | 2012-02-09 | 2021-02-16 | University Of Kansas | C-terminal hsp90 inhibitors |
| BR112014029301A2 (pt) * | 2012-05-25 | 2017-07-25 | Berg Llc | métodos de tratamento de síndrome metabólica através de modulação da proteína choque térmico (hsp) 90-beta |
| TWI671083B (zh) | 2014-03-20 | 2019-09-11 | 日商大塚製藥股份有限公司 | 醫藥調製劑 |
| AU2015269054A1 (en) | 2014-06-06 | 2017-01-12 | Berg Llc | Methods of treating a metabolic syndrome by modulating heat shock protein (HSP) 90-beta |
| CA3168495A1 (en) * | 2020-01-20 | 2021-07-29 | Neophore Limited | Isoindoline derivatives which bind to an atp binding site |
| CN114767683A (zh) * | 2022-04-29 | 2022-07-22 | 暨南大学 | Onalespib在制备预防和/或治疗腺病毒感染的药物中的应用 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2262952C2 (ru) * | 2000-04-06 | 2005-10-27 | Ньютек Фарма Плс | ЛЕЧЕНИЕ ГРИБКОВОЙ ИНФЕКЦИИ ПРОТИВОГРИБКОВЫМИ ПРЕПАРАТАМИ ИЗ ГРУППЫ ПОЛИЕНОВ ИЛИ ИНГИБИТОРОВ β-ГЛЮКАНСИНТАЗЫ В КОМБИНАЦИИ С АНТИ-hsp90-АНТИТЕЛАМИ |
Family Cites Families (102)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5540563Y2 (enExample) | 1972-04-26 | 1980-09-22 | ||
| JPS4910506A (enExample) | 1972-05-31 | 1974-01-30 | ||
| US4582909A (en) * | 1984-02-02 | 1986-04-15 | Warner-Lambert Company | Benzobicyclic lactam acids and derivatives as cognition activators |
| US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| US4760064A (en) * | 1984-12-18 | 1988-07-26 | Otsuka Pharmaceutical Co., Ltd. | Carbostyril compounds, compositions containing same and processes for preparing same |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| CA1340191C (en) | 1988-06-13 | 1998-12-15 | Katsuhiro Imaki | Derivatives of p-substituted phenyl ester of pivalic acid |
| US4990511A (en) | 1988-08-03 | 1991-02-05 | Takeda Chemical Industries, Ltd. | Amide compounds, their production and use |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| GB8926560D0 (en) | 1989-11-24 | 1990-01-17 | Zambeletti Spa L | Pharmaceuticals |
| US5124350A (en) * | 1990-06-28 | 1992-06-23 | G. D. Searle & Co. | Leukotriene b4 antagonists |
| ZA916555B (en) | 1990-08-27 | 1993-04-28 | Lilly Co Eli | Method of treating inflammatory bowel disease |
| FR2669029B1 (fr) | 1990-11-14 | 1994-09-02 | Adir | Nouveaux derives de la n-benzoyl proline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
| US5280046A (en) | 1991-02-22 | 1994-01-18 | The University Of Colorado Foundation, Inc. | Method of treating type I diabetes |
| WO1992017467A1 (en) | 1991-04-06 | 1992-10-15 | Dr Lo. Zambeletti S.P.A. | Substituted azacyclic compounds, process for their preparation and their use as analgesics |
| US5619092A (en) * | 1993-02-01 | 1997-04-08 | Motorola | Enhanced electron emitter |
| US5633283A (en) | 1995-01-23 | 1997-05-27 | Eli Lilly And Company | Method for treating multiple sclerosis |
| JPH0910506A (ja) | 1995-06-30 | 1997-01-14 | Toshiba Corp | 脱気器 |
| US5882864A (en) | 1995-07-31 | 1999-03-16 | Urocor Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate disease |
| US6218529B1 (en) | 1995-07-31 | 2001-04-17 | Urocor, Inc. | Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer |
| JP3855026B2 (ja) | 1996-01-16 | 2006-12-06 | 富士レビオ株式会社 | アミド誘導体の製造方法 |
| DE69739970D1 (de) | 1996-01-29 | 2010-10-07 | Univ California | Methode zur behandlung sexueller fehlfunktionen |
| GB9606187D0 (en) | 1996-03-23 | 1996-05-29 | Inst Of Food Research | Production of vanillin |
| JP2000507955A (ja) | 1996-04-03 | 2000-06-27 | メルク エンド カンパニー インコーポレーテッド | ファルネシル―タンパク質転移酵素の阻害剤 |
| EP0918518A4 (en) | 1996-04-19 | 2002-05-02 | Univ California | TREATMENT OF MIND AND MOOD DISEASES WITH GLUTAMATERGIC MODULATORS. |
| IL118657A0 (en) | 1996-06-14 | 1996-10-16 | Arad Dorit | Inhibitors for picornavirus proteases |
| WO1998040385A1 (en) | 1997-03-07 | 1998-09-17 | Novo Nordisk A/S | 4,5,6,7-TETRAHYDRO-THIENO[3,2-c]PYRIDINE DERIVATIVES, THEIR PREPARATION AND USE |
| UY24949A1 (es) | 1997-04-08 | 2001-04-30 | Smithkline Beecham Corp | Compuestos calcilíticos |
| EP0975614A1 (en) | 1997-04-18 | 2000-02-02 | Smithkline Beecham Plc | A bicyclic aryl or a bicyclic heterocyclic ring containing compounds having a combined 5ht1a, 5ht1b and 5ht1d receptor antagonistic activity |
| US6329368B1 (en) | 1997-05-09 | 2001-12-11 | The Regents Of The University Of California | Endocrine modulation with positive modulators of AMPA type glutamate receptors |
| WO1999021422A1 (en) | 1997-10-27 | 1999-05-06 | Cortex Pharmaceuticals, Inc. | Treatment of schizophrenia with ampakines and neuroleptics |
| AU1804299A (en) | 1997-12-08 | 1999-06-28 | Glycomed Incorporated | Sialyl lewis x and sialyl lewis a glycomimetics |
| WO2000059867A1 (en) | 1999-03-30 | 2000-10-12 | Pharmacor Inc. | Hydroxyphenyl derivatives with hiv integrase inhibitory properties |
| DE19955283A1 (de) | 1999-11-17 | 2001-05-23 | Aventis Res & Tech Gmbh & Co | Verfahren zur enantioselektiven Gewinnung von Aminosäuren und Aminosäurederivaten unter Verwendung von Racemisierungskatalysatoren |
| US6677473B1 (en) | 1999-11-19 | 2004-01-13 | Corvas International Inc | Plasminogen activator inhibitor antagonists |
| WO2001060369A1 (en) | 2000-02-18 | 2001-08-23 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
| WO2001085695A1 (en) * | 2000-05-11 | 2001-11-15 | Bristol-Myers Squibb Co. | Tetrahydroisoquinoline analogs useful as growth hormone secretagogues |
| US7229986B2 (en) * | 2000-05-16 | 2007-06-12 | Takeda Pharmaceutical Company Ltd. | Melanin-concentrating hormone antagonist |
| DE10024939A1 (de) * | 2000-05-19 | 2001-11-29 | Bayer Ag | Neue Diphenylmethanderivate für Arzneimittel |
| CA2308994A1 (en) | 2000-05-19 | 2001-11-19 | Aegera Therapeutics Inc. | Neuroprotective compounds |
| FR2812876B1 (fr) | 2000-08-08 | 2002-09-27 | Galderma Res & Dev | Nouveaux composes bi-aromatiques activateurs des recepteurs de type ppar-gamma et leur utilisation dans des compositions cosmetiques ou pharmaceutiques |
| IL154507A0 (en) | 2000-08-25 | 2003-09-17 | Warner Lambert Co | Process for making n-aryl-anthranilic acids and their derivatives |
| UA82827C2 (en) * | 2000-12-18 | 2008-05-26 | Inhibitors against the production and release of inflammatory cytokines | |
| WO2003051877A1 (en) | 2001-12-18 | 2003-06-26 | Bayer Corporation | 2-substituted pyrrolo[2.1-a]isoquinolines against cancer |
| DE60235500D1 (de) | 2001-12-20 | 2010-04-08 | Osi Pharm Inc | Selektive pyrimidin-a2b-antagonistenverbindungen, ihre synthese und verwendung |
| US7247734B2 (en) | 2001-12-21 | 2007-07-24 | Vernalis (Cambridge) Limited | 3,4-diarylpyrazoles and their use in the therapy of cancer |
| WO2003086282A2 (en) | 2002-04-05 | 2003-10-23 | Nitromed, Inc. | Nitric oxide donors, compositions and methods of use |
| JPWO2003103658A1 (ja) | 2002-06-05 | 2005-10-06 | 株式会社医薬分子設計研究所 | 免疫関連プロテインキナーゼ阻害剤 |
| AU2003242127A1 (en) | 2002-06-05 | 2003-12-22 | Institute Of Medicinal Molecular Design, Inc. | Inhibitors against the activation of ap-1 and nfat |
| EP1510207A4 (en) | 2002-06-05 | 2008-12-31 | Inst Med Molecular Design Inc | THERAPEUTIC MEDICAMENT AGAINST DIABETES |
| US20060122243A1 (en) | 2002-06-06 | 2006-06-08 | Susumu Muto | Antiallergic |
| SE0202133D0 (sv) | 2002-07-08 | 2002-07-08 | Astrazeneca Ab | Novel compounds |
| JP2006504651A (ja) | 2002-07-16 | 2006-02-09 | アミュラ テラピューティクス リミテッド | 生物活性化合物 |
| AU2003287160A1 (en) | 2002-10-15 | 2004-05-04 | Rigel Pharmaceuticals, Inc. | Substituted indoles and their use as hcv inhibitors |
| TWI228885B (en) | 2003-01-23 | 2005-03-01 | Mediatek Inc | Method for controlling a mobile communication device to enter a power-saving mode and to recover timing after the mobile communication device leaves the power-saving mode |
| MXPA05008335A (es) | 2003-02-11 | 2006-05-04 | Vernalis Cambridge Ltd | Compuestos de isoxazol como inhibidores de las proteinas de choque por calor. |
| AU2003223226A1 (en) * | 2003-02-20 | 2004-09-17 | University Of Connecticut Health Center | Methods for using compositions comprising heat shock proteins or alpha-2-macroglobulin in the treatment of cancer and infectious disease |
| EP1597256A1 (en) | 2003-02-21 | 2005-11-23 | Pfizer Inc. | N-heterocyclyl-substituted amino-thiazole derivatives as protein kinase inhibitors |
| WO2004078756A2 (en) | 2003-03-06 | 2004-09-16 | Eisai Co., Ltd. | Jnk inhibitors |
| CA2523677A1 (en) | 2003-04-30 | 2004-11-11 | Novartis Ag | Aminopropanol derivatives as sphingosine-1-phosphate receptor modulators |
| GB0315111D0 (en) | 2003-06-27 | 2003-07-30 | Cancer Rec Tech Ltd | Substituted 5-membered ring compounds and their use |
| ES2432747T3 (es) | 2003-06-27 | 2013-12-05 | Kyowa Hakko Kirin Co., Ltd. | Inhibidores de proteínas de la familia HSP90 |
| TWI312345B (en) | 2003-06-30 | 2009-07-21 | Mitsubishi Tanabe Pharma Corp | Process of preparating 3-acylaminobenzofuran-2-carboxylic acid derivatives |
| RU2006104697A (ru) * | 2003-07-16 | 2006-06-27 | Инститьют Оф Медисинал Молекьюлар Дизайн. Инк. (Jp) | Лекарственное средство для лечения пигментации кожи |
| BRPI0412259B1 (pt) | 2003-07-22 | 2019-08-20 | Astex Therapeutics Limited | Compostos de 1H-pirazol 3,4-dissubstituídos como moduladores de quinases dependentes de ciclina (CDK), seus usos, processo para a preparação dos mesmos e composição farmacêutica |
| ZA200510137B (en) | 2003-07-24 | 2007-04-25 | Leo Pharma As | Novel aminobenzophenone compounds |
| SI1660492T1 (sl) | 2003-07-28 | 2009-02-28 | Janssen Pharmaceutica Nv | Benzimidazolni, benztiazolni in benzoksazolni derivati in njihova uporaba kot modulatorji LTA4H |
| DE10335584B4 (de) * | 2003-07-31 | 2006-06-29 | Philipps-Universität Marburg | Verfahren zur Herstellung zyklischer Moleküle |
| DE10335726A1 (de) * | 2003-08-05 | 2005-03-03 | Bayer Cropscience Gmbh | Verwendung von Hydroxyaromaten als Safener |
| WO2005016889A1 (en) | 2003-08-08 | 2005-02-24 | Virginia Commonwealth University | Compounds having antiestrogenic and tissue selective estrogenic properties |
| CA2572750A1 (en) | 2003-09-10 | 2005-03-17 | Anil Koul | Heterobicyclic compounds as pharmaceutically active agents |
| EP1680137B1 (en) | 2003-10-14 | 2012-11-21 | F. Hoffmann-La Roche Ltd. | Macrocyclic carboxylic acid and acylsulfonamide compound as inhibitor of HCV replication |
| RU2006120084A (ru) | 2003-11-10 | 2008-01-10 | Шеринг Акциенгезельшафт (De) | Бензилэфирамины, полезные как антагонисты ccr-5 |
| WO2005063222A1 (ja) | 2003-12-26 | 2005-07-14 | Kyowa Hakko Kogyo Co., Ltd. | Hsp90ファミリー蛋白質阻害剤 |
| US7351709B2 (en) * | 2004-06-09 | 2008-04-01 | Wyeth | Estrogen receptor ligands |
| KR20070053237A (ko) | 2004-07-27 | 2007-05-23 | 에스지엑스 파마슈티컬스, 인코포레이티드 | 피롤로-피리딘 키나제 조절제 |
| AU2005277223C1 (en) * | 2004-08-20 | 2009-05-21 | The Regents Of The University Of Michigan | Small molecule inhibitors of anti-apoptotic Bcl-2 family members and the uses thereof |
| DE102004049078A1 (de) | 2004-10-08 | 2006-04-13 | Merck Patent Gmbh | Phenylpyrazole |
| US7208630B2 (en) * | 2004-10-27 | 2007-04-24 | University Of Kansas | Heat shock protein 90 inhibitors |
| US7781485B2 (en) * | 2004-11-09 | 2010-08-24 | Kyowa Hakko Kirin Co., Ltd. | Hsp90 family protein inhibitors |
| CN101072759B (zh) * | 2004-11-18 | 2013-06-19 | Synta医药公司 | 调节hsp90活性的三唑化合物 |
| US8110573B2 (en) | 2004-12-30 | 2012-02-07 | Astex Therapeutics Limited | Pyrazole compounds that modulate the activity of CDK, GSK and aurora kinases |
| AR054425A1 (es) | 2005-01-21 | 2007-06-27 | Astex Therapeutics Ltd | Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico. |
| ES2334578T3 (es) * | 2005-02-07 | 2010-03-12 | F. Hoffmann-La Roche Ag | Fenil-metanonas sustituidas por heterociclo como inhibidores del transportador 1 de la glicina. |
| WO2006088954A1 (en) * | 2005-02-15 | 2006-08-24 | Janssen Pharmaceutica, N.V. | Dihydroindolyl methanones as alpha 1a/1d adrenoreceptor modulators for the treatment of benign prostatic hypertrophy and lower urinary tract symptoms |
| CN101123954B (zh) | 2005-02-21 | 2011-07-13 | 协和发酵麒麟株式会社 | 抗肿瘤剂 |
| PL1877379T3 (pl) * | 2005-04-13 | 2013-06-28 | Astex Therapeutics Ltd | Pochodne hydroksybenzamidu i ich wykorzystanie, jako inhibitorów hsp90 |
| JP2008540395A (ja) | 2005-05-03 | 2008-11-20 | ファイザー・インク | アミドレソルシノール化合物 |
| EP2444079B1 (en) | 2005-05-17 | 2016-11-30 | SARcode Bioscience Inc. | Compositions and Methods for Treatment of Eye Disorders |
| WO2007050124A1 (en) | 2005-05-19 | 2007-05-03 | Xenon Pharmaceuticals Inc. | Fused piperidine derivatives and their uses as therapeutic agents |
| US7425633B2 (en) * | 2005-08-26 | 2008-09-16 | National Health Research Institutes | Pyrrolidine compounds |
| EP1808634B1 (en) * | 2006-01-12 | 2008-10-29 | Ondal Holding GmbH | Fixture to mount a device |
| US7754725B2 (en) * | 2006-03-01 | 2010-07-13 | Astex Therapeutics Ltd. | Dihydroxyphenyl isoindolymethanones |
| US8883790B2 (en) * | 2006-10-12 | 2014-11-11 | Astex Therapeutics Limited | Pharmaceutical combinations |
| US8277807B2 (en) * | 2006-10-12 | 2012-10-02 | Astex Therapeutics Limited | Pharmaceutical combinations |
| WO2008044054A2 (en) | 2006-10-12 | 2008-04-17 | Astex Therapeutics Limited | Hydroxy-substituted benzoic acid amide compounds for use in therapy |
| JP5410285B2 (ja) * | 2006-10-12 | 2014-02-05 | アステックス、セラピューティックス、リミテッド | 医薬化合物 |
| EP2073803B1 (en) | 2006-10-12 | 2018-09-19 | Astex Therapeutics Limited | Pharmaceutical combinations |
| GB0620259D0 (en) | 2006-10-12 | 2006-11-22 | Astex Therapeutics Ltd | Pharmaceutical compounds |
| WO2008053319A1 (en) | 2006-10-30 | 2008-05-08 | Pfizer Products Inc. | Amide resorcinol compounds |
-
2006
- 2006-10-12 GB GBGB0620259.2A patent/GB0620259D0/en not_active Ceased
-
2007
- 2007-10-11 TW TW096138174A patent/TWI429638B/zh not_active IP Right Cessation
- 2007-10-12 WO PCT/GB2007/003871 patent/WO2008044034A1/en not_active Ceased
- 2007-10-12 HU HUE12187611A patent/HUE037268T2/hu unknown
- 2007-10-12 PL PL07824125T patent/PL2081895T3/pl unknown
- 2007-10-12 RS RS20130118A patent/RS52716B/sr unknown
- 2007-10-12 RS RS20180350A patent/RS57079B1/sr unknown
- 2007-10-12 EP EP07824125A patent/EP2081895B1/en active Active
- 2007-10-12 PT PT78241254T patent/PT2081895E/pt unknown
- 2007-10-12 HR HRP20130255TT patent/HRP20130255T1/hr unknown
- 2007-10-12 LT LTEP12187611.4T patent/LT2546233T/lt unknown
- 2007-10-12 PT PT121876114T patent/PT2546233T/pt unknown
- 2007-10-12 ES ES07824125T patent/ES2402903T3/es active Active
- 2007-10-12 PL PL12187611T patent/PL2546233T3/pl unknown
- 2007-10-12 ME MEP-2013-34A patent/ME01874B/me unknown
- 2007-10-12 CA CA2665931A patent/CA2665931C/en not_active Expired - Fee Related
- 2007-10-12 NZ NZ576110A patent/NZ576110A/en not_active IP Right Cessation
- 2007-10-12 KR KR1020097009666A patent/KR101571568B1/ko not_active Expired - Fee Related
- 2007-10-12 EP EP12187611.4A patent/EP2546233B1/en active Active
- 2007-10-12 SI SI200732010T patent/SI2546233T1/en unknown
- 2007-10-12 DK DK12187611.4T patent/DK2546233T3/en active
- 2007-10-12 AU AU2007306104A patent/AU2007306104B2/en not_active Ceased
- 2007-10-12 ES ES12187611.4T patent/ES2662359T3/es active Active
- 2007-10-12 MX MX2009003739A patent/MX2009003739A/es active IP Right Grant
- 2007-10-12 BR BRPI0719879A patent/BRPI0719879A8/pt not_active Application Discontinuation
- 2007-10-12 US US12/445,130 patent/US8653084B2/en not_active Expired - Fee Related
- 2007-10-12 DK DK07824125.4T patent/DK2081895T3/da active
- 2007-10-12 RU RU2009117589/04A patent/RU2490258C2/ru not_active IP Right Cessation
- 2007-10-12 CN CN2007800455503A patent/CN101848892B/zh not_active Expired - Fee Related
- 2007-10-12 SI SI200731206T patent/SI2081895T1/sl unknown
- 2007-10-12 JP JP2009531915A patent/JP5726416B2/ja active Active
-
2009
- 2009-04-01 ZA ZA2009/02270A patent/ZA200902270B/en unknown
- 2009-04-05 IL IL197934A patent/IL197934A/en active IP Right Grant
- 2009-05-12 NO NO20091858A patent/NO342242B1/no not_active IP Right Cessation
-
2013
- 2013-04-03 CY CY20131100278T patent/CY1113873T1/el unknown
-
2014
- 2014-01-07 US US14/149,450 patent/US9428439B2/en not_active Expired - Fee Related
-
2018
- 2018-03-02 HR HRP20180375TT patent/HRP20180375T1/hr unknown
- 2018-03-19 CY CY20181100318T patent/CY1120081T1/el unknown
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2262952C2 (ru) * | 2000-04-06 | 2005-10-27 | Ньютек Фарма Плс | ЛЕЧЕНИЕ ГРИБКОВОЙ ИНФЕКЦИИ ПРОТИВОГРИБКОВЫМИ ПРЕПАРАТАМИ ИЗ ГРУППЫ ПОЛИЕНОВ ИЛИ ИНГИБИТОРОВ β-ГЛЮКАНСИНТАЗЫ В КОМБИНАЦИИ С АНТИ-hsp90-АНТИТЕЛАМИ |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2490258C2 (ru) | ПРОИЗВОДНЫЕ ГИДРОБЕНЗАМИДА В КАЧЕСТВЕ ИНГИБИТОРОВ Hsp90 | |
| CN100390148C (zh) | 用于治疗恶性肿瘤的药物 | |
| CA2606719A1 (en) | Amorphous salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide and process for producing the same | |
| CN107530556A (zh) | Dna烷化剂 | |
| JP2005528325A5 (enExample) | ||
| RU2014151565A (ru) | Способ получения n-[5-(3,5-дифторбензил)-1н-индазол-3-ил]-4-(4-метилпиперазин-1-ил)-2-(тетрагидропиран-4-иламино)бензамида | |
| JPH0347157A (ja) | 殺生物性芳香族化合物、その合成および医薬としてのその使用 | |
| JPWO2014017515A1 (ja) | ４−［５−（ピリジン−４−イル）−１ｈ−１，２，４−トリアゾール−３−イル］ピリジン−２−カルボニトリルの結晶多形およびその製造方法 | |
| CA3063111A1 (en) | Histone deacetylases (hdacs) inhibitors | |
| JP2010526136A (ja) | ドーパミン−β−ヒドロキシラーゼの阻害剤としての１，３−ジヒドロイミダゾール−２−チオン誘導体 | |
| Shinde et al. | Microwave induced synthesis of bis-Schiff bases from propane-1, 3-diamine as promising antimicrobial analogs | |
| Antoszczak et al. | Synthesis and antiproliferative activity of new bioconjugates of Salinomycin with amino acid esters | |
| Islam et al. | Therapeutic potential of N4-substituted thiosemicarbazones as new urease inhibitors: Biochemical and in silico approach | |
| JP2020528076A (ja) | 医薬化合物 | |
| CN110770234A (zh) | 取代芳基醚类化合物、其制备方法、药用组合物及其应用 | |
| EP2647622B1 (en) | Kinesin spindle protein inhibitors and application thereof | |
| NO20004162L (no) | Antitumor agens | |
| JP2017503753A5 (enExample) | ||
| EP1991233A2 (en) | Hydroxypiperidine derivatives and uses thereof | |
| RU2007143509A (ru) | Производные ацетилена | |
| CN101638389A (zh) | 一种含萘酰亚胺结构的多胺衍生物及其制备方法和应用 | |
| CN113735828A (zh) | 一种靶向降解egfr的化合物及其制备方法和应用 | |
| CN1132506A (zh) | 用于治疗癌症的新双萘二甲酰亚胺 | |
| CN111116469A (zh) | 一种hdac抑制剂、制备方法、药物组合物及其用途 | |
| CN104974108B (zh) | 一类2,2’‑串联双噻唑类化合物及其制备方法和用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20201013 |